hubXchange

🚀 Can oligonucleotide therapies move beyond rare disease? Join us for a dynamic roundtable discussion: "Expanding the Clinical Applications of Oligonucleotide Therapies: From Rare Diseases to Broader Indications" 🗓️ 26 June 2025 | 09:05 – 10:05 📍 New Modalities Track | Oligonucleotide Therapeutics Xchange – Boston 2025 With oligonucleotide drugs already transforming care in SMA and DMD, what will it take to bring this promise to oncology, cardiometabolic, and inflammatory diseases? 💡 Key topics we’ll explore: 🔶 What have we learned from approved oligos, and how can we expand their reach? 🔶 The latest in extrahepatic delivery, BBB penetration, and cellular uptake 🔶 How to design trials and safety strategies that support broader population use 🎙️ Led by: Debasis Patra, VP, Head of CMC – OliX Pharmaceuticals, Inc. 🔗 Seats are limited for this invite-only discussion → Register your FREE pass https://lnkd.in/eS7hk5ck For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #OligonucleotideTherapeutics #DrugDelivery #RNAtherapeutics #BiotechInnovation #NewModalities #ClinicalDevelopment #hubXchange #BostonBiotech #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

🚨 Tackling the Undruggable with AI? Let’s Talk Reality. Join us at the Antibody Therapeutics Xchange – Boston for a Poster Presentation that cuts through the AI hype and dives into how next-gen platforms are truly moving the needle in antibody discovery. 🗓 Date: June 23, 2025 🕒 Time: 15:50 - 16:20 📍 Track: Formats & Scaffolds Poster Title: 👉 Tackling challenging targets with AI-driven antibody discovery and engineering platform 🔍 What’s in store: Real-world case studies from Ailux Biologics (XtalPi) Discover how the AtlaX biologics database + proprietary AI engines + full-stack wet lab deliver functional antibodies Get an evidence-based look at AI’s impact on multi-objective antibody optimization 🎙 Meet the expert: Yuhao (Arthur) Wang, Ph.D. Technical Communications Lead – Ailux (XtalPi) With a background spanning academic science, BD, and biotech VC, Arthur brings a rare perspective on the intersection of AI, biology, and innovation strategy. 🔗 Spots are limited – secure your FREE place to hear how AI is actually being used to tackle hard targets in antibody engineering. https://lnkd.in/epbCpYuJ For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #AntibodyTherapeutics #AIinBiotech #AntibodyDiscovery #ProteinEngineering #BiologicsInnovation #XtalPi #AiluxBiologics #DrugDiscovery #AntibodyXchange #LifeSciencesEvents #AIforDrugDiscovery #BostonBiotech #FormatsAndScaffolds #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

💡 Potency isn’t just a measurement—it’s a make-or-break factor in CGT manufacturing. But how do you successfully transfer such assays from development to GMP execution? Find out at the Spotlight Presentation: “Potency Assay Technical Transfer Best Practice” 🗓 June 17, 2025 | 13:25 – 13:55 📍 Immunotherapies Xchange – Boston 2025 Join Joseph Newcome, Senior Director at Minaris Advanced Therapies, as he shares real-world strategies, case studies, and lessons learned from decades at the intersection of microbiology, GMP, and advanced therapeutic manufacturing. 🔍 Expect insights on: 🟣Why potency assays for CGTs demand individual development and validation 🟣Critical milestones in tech transfer: from assessment to execution 🟣Best practices from a CDMO perspective to ensure quality, consistency, and clinical success 🎯 If you work in analytical development, QC, or CMC for ATMPs—this is a must-attend session. Secure your FREE spot 👉https://lnkd.in/esxK8PyE For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #AdvancedTherapies #CellTherapy #GeneTherapy #PotencyAssays #TechTransfer #AnalyticalDevelopment #CGTManufacturing #GMP #BiotechEvents #ImmunotherapiesXchange #hubXchange #BostonBiotech #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

How do you ensure your cell or gene therapy product makes it from lab to clinic with confidence? 👉 It all starts with robust potency assay development and successful tech transfer. Join us for a Spotlight Presentation at the Advanced Therapies Xchange – Boston 2025 on: 🗓️ June 24 🕜 13:25 – 13:55 📍 The Westin Waltham, Boston 🔬 Session: Potency Assay Technical Transfer Best Practice Led by Dr. Heather Malicki, Ph.D., Executive Director, Analytical Development & Quality Control – Minaris Advanced Therapies Heather will share real-world case studies and best practices for tackling one of the most challenging areas in CGT manufacturing: ✔️ Tailoring and validating potency assays for ATMPs ✔️ Key milestones and readiness in successful tech transfer ✔️ The role of CDMOs in ensuring GMP standards and regulatory success 💡 Whether you’re scaling up for clinical trials or preparing for commercialization, this is a must-attend for professionals navigating advanced therapy manufacturing. 🎟️ Registration is free for senior-level professionals from biotech and pharma: 👉 Register for FREE now – limited seats remain! For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #CellTherapy #GeneTherapy #ATMP #PotencyAssays #TechTransfer #CGTManufacturing #AdvancedTherapies #CDMO #Biotech #Biomanufacturing #GMP #hubXchange #BostonBiotech #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

💥 How can we best tune the potency, tolerability, and PK properties of ADC payloads to optimally address specific targets and disease contexts? 🧠 Join Nicholas Yoder, Executive Director at Dyne Therapeutics, for an in-depth roundtable discussion: 🗓️ 18 June 2025 🕘 09:05 - 10:05 📍 Cytotoxic Payload Track 📌 Antibody Drug Conjugate Therapeutics Xchange - Boston - 2025 🔬 Key discussion points: • How do you optimize payload potency and DAR for specific target receptors and disease indications? • How important is high antibody dose when targeting solid tumors? • How to test ADC biophysical properties to ensure optimal pharmacokinetic properties of the ADC? • Dual trigger ADCs: can you increase therapeutic index via multiple prodrug triggers? • What is the next payload MoA that could drive ADCs forward beyond topoisomerase inhibitors? 👤 Nicholas C. Yoder, Ph.D., is a chemist with experience spanning ADC design at ImmunoGen—where he contributed to programs like pivekimab sunirine and IMGC936—to stem cell conditioning ADCs at Magenta Therapeutics. He now focuses on receptor-targeted oligonucleotide conjugates for genetic diseases at Dyne Therapeutics. 👉 Secure your place at the table and contribute to this essential conversation! REGISTER FOR FREE: https://lnkd.in/dHbMAgad For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #AntibodyDrugConjugates #ADCTherapeutics #OncologyInnovation #CancerResistance #DrugDelivery #CytotoxicPayloads #Bioconjugation #TargetedTherapies #BiotechEvents #PharmaR&D #BostonBiotech #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

Structure-based drug design meets machine learning—what’s the future of H2L? Join us 🗓️ June 25th, 2025, 09:05–10:05 at the AI in Drug Discovery Xchange – Boston for an interactive roundtable discussion: 🔬 “H2L and optimization with structure-based drug design and machine learning” 🧠 Key topics on the table: 🧪 Hit tractability and the H2L journey 🧬 Rational drug design vs. modern AI/ML methods 🧫 QSAR models and protein–ligand interaction fingerprinting ⚗️ Potency and physicochemical properties as MPO functions 👨🔬 Led by: Chris Mulhern, Head of Machine Learning & Data Science Computation at Orogen Therapeutics – with experience spanning 200+ DEL campaigns and leadership roles at X-Chem, ZebiAI, Relay, Terray, and Animol. Chris blends cutting-edge ML, cheminformatics, and real-world drug discovery know-how to accelerate H2L innovation. 🔎 If you're exploring AI integration, tackling tractability, or evolving your lead optimization pipeline—this roundtable is your lab bench for new ideas. 🔗 Register now to reserve your seat at the table! Claim Your FREE Pass: https://lnkd.in/eqMB7P5r For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #DrugDiscovery #MachineLearning #StructureBasedDesign #Cheminformatics #QSAR #HitToLead #ComputationalChemistry #AIinPharma #BiotechInnovation #LeadOptimization #AIinDrugDiscovery #BostonBiotech #PharmaR&D #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

We’re kicking off Antibody Therapeutics Xchange – Boston – 2025 with a powerful Opening Address & Keynote Presentation you won’t want to miss: 🧬 “The Truth About Antibodies and Polyspecificity” 📅 23 June 2025 🕣 08:30 – 09:00 Antibodies are designed to be specific—but what happens when they’re not? Up to 1 in 3 antibody drugs may display off-target binding, posing serious challenges in safety, efficacy, and drug attrition. In this keynote, Rachel Fong, Senior Director, MPA Commercial Operations at Integral Molecular, uncovers the hidden pitfalls of polyspecificity and reveals how cell-based protein arrays, including the cutting-edge Membrane Proteome Array, are transforming the way we assess antibody specificity. Rachel brings over a decade of experience and was part of the founding team that launched the MPA platform. With her deep expertise, this session promises actionable insights and a glimpse into the future of antibody characterization. 🔍 Let’s rethink what we know about antibody behavior—starting from the very first step. 📍 Secure your spot and start your Xchange experience with science that matters. 👉 Secure your COMPLIMENTARY pass: https://lnkd.in/gFmqRAek For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #AntibodyTherapeutics #Polyspecificity #DrugDevelopment #Biologics #OffTargetBinding #Immunology #MembraneProteomeArray #BiotechInnovation #IntegralMolecular #ProteinArrays #Xchange2025 #BostonBiotech #KeynoteScience #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

🧬 How can we harness regulatory T cells to achieve durable immune tolerance? Join the conversation at Immunotherapies Xchange – Boston – 2025, where we’ll dive into cutting-edge strategies for expanding and transferring regulatory T cells (Tregs) to modulate immune responses and enhance tolerance in autoimmune and inflammatory conditions. 📅 17 June 2025 🕒 15:50 – 16:50 🔬 Immune Regulation Track 💡 Roundtable title: Expanding and transferring regulatory T cells to enhance immune tolerance Leading the discussion is Dr. Seng-Lai "Thomas" Tan, Ph.D., Chief Scientific Officer at TFC Therapeutics. A seasoned drug hunter and translational science leader, Dr. Tan brings a wealth of experience across immuno-oncology, autoimmunity, and T cell biology—having led programs targeting TGFβ, IL-6, TL1A, and more. Expect deep insights on: ✔️Autologous or allogeneic? Choosing the right Treg therapy for the right setting ✔️Tailoring Tregs to disease type: Chronic vs acute — what works best and why ✔️Treg flavors decoded: Natural, induced, and Tr1 — mechanisms, advantages, and trade-offs ✔️Precision matters: Navigating specificity, avidity, and HLA-restriction in TCR-engineered Tregs ✔️Broad vs targeted: Polyclonal and antigen-specific strategies — where each shines and where they fall short 🎟️ Registration is now open – secure your spot to contribute and collaborate with fellow immunology experts: SECURE YOUR FREE PASS: https://lnkd.in/g6kgQGRm For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #Immunotherapy #RegulatoryTCells #ImmuneTolerance #CellTherapy #TranslationalScience #Autoimmunity #Tregs #ImmunologyInnovation #BiotechEvents #DrugDiscovery #ImmunotherapiesXchange #Boston2025 #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

🧬 How do you truly validate a gene therapy process when every variable counts? Let’s face it — process validation in gene therapy manufacturing isn't just complex, it's critical. From designing representative scale-down models to qualifying them with robust analytics, there’s little room for error when you're dealing with life-changing therapies. 🔍 That’s why we’re bringing the sharpest minds together for a roundtable discussion you won’t want to miss: “Advancing Process Validation in Gene Therapy: Best Practices for Scale-Down Models & Characterization” 📅 24 June 2025 🕒 15:50 – 16:50 📍 Gene Therapy Manufacturing Track – Advanced Therapies Xchange, Boston Led by industry expert Ankur Desai, VP Analytical Development at Aura Biosciences, This session will dive into: ✅ Top challenges in gene therapy process characterization ✅ Building and qualifying scale-down models that actually reflect reality ✅ Analytical strategies that satisfy regulators and accelerate timelines ✅ The growing role of AI in real-time monitoring and predictive analytics If you work in CMC, analytics, validation, or manufacturing sciences, this is your chance to benchmark strategies and swap ideas with fellow leaders. 📌 Spaces are limited — reserve your FREE seat today! 🔗 https://lnkd.in/eQ39-Rfh For Senior Scientists and above in Bio and Pharma companies with a drug pipeline only. 💊 #GeneTherapy #ProcessValidation #AdvancedTherapies #Biomanufacturing #CellAndGeneTherapy #AIinBiotech #Bioprocessing #AnalyticsInBiotech #RegulatoryScience #Xchange2025 #BostonBiotech #ScaleDownModels #GMP #ATMPs #CMC #PharmaLeadership #CGTStrategy #RoundtableDiscussion #PharmaXchange #RoundtableDiscussion #NetworkingOpportunities #Collaboration #hubXchange #Xchanges #Roundtable #RegisterNow #ComplimentaryPass #FreePass

Look forward to meeting everyone next month at Antibody Therapeutic Xchange in Boston!